Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)
SS Yom, P Torres-Saavedra, JJ Caudell… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Reducing radiation treatment dose could improve the quality of life (QOL) of
patients with good-risk human papillomavirus–associated oropharyngeal squamous cell …
patients with good-risk human papillomavirus–associated oropharyngeal squamous cell …
Mature results of a prospective study of deintensified chemoradiotherapy for low‐risk human papillomavirus‐associated oropharyngeal squamous cell carcinoma
BACKGROUND The purpose of the current study was to determine quality of life and tumor
control from a prospective phase 2 clinical trial evaluating deintensified chemoradiotherapy …
control from a prospective phase 2 clinical trial evaluating deintensified chemoradiotherapy …
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation
B O'Sullivan, SH Huang, B Perez-Ordonez… - Radiotherapy and …, 2012 - Elsevier
PURPOSE: To report outcome of HPV-related [HPV (+)] oropharyngeal cancer (OPC)
managed predominantly by altered-fractionation radiotherapy-alone (RT-alone). METHODS …
managed predominantly by altered-fractionation radiotherapy-alone (RT-alone). METHODS …
[HTML][HTML] De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma—A narrative review
MP Strohl, KC Wai, PK Ha - Annals of translational medicine, 2020 - ncbi.nlm.nih.gov
Abstract Human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinoma
(OPSCC) is a relatively new clinical entity that is dramatically on the rise globally. HPV+ …
(OPSCC) is a relatively new clinical entity that is dramatically on the rise globally. HPV+ …
Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma
BS Chera, RJ Amdur, J Tepper, B Qaqish… - International Journal of …, 2015 - Elsevier
Purpose To perform a prospective, multi-institutional, phase 2 study of a substantial
decrease in concurrent chemoradiation therapy (CRT) intensity as primary treatment for …
decrease in concurrent chemoradiation therapy (CRT) intensity as primary treatment for …
Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial
Abstract Background Human Papillomavirus oropharyngeal carcinoma (HPVOPC) has
better progression free (PFS) and overall survival (OS) than non-HPVOPC. Standard-dose …
better progression free (PFS) and overall survival (OS) than non-HPVOPC. Standard-dose …
Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus–associated oropharyngeal carcinoma treated with …
Importance Several de-escalation strategies for human papillomavirus (HPV)–associated
oropharyngeal carcinoma (OPC) have focused on deintensifying gross disease treatment …
oropharyngeal carcinoma (OPC) have focused on deintensifying gross disease treatment …
Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a …
AC Nichols, P Lang, E Prisman, E Berthelet, E Tran… - BMC cancer, 2020 - Springer
Background Patients with human papillomavirus-positive (HPV+) oropharyngeal squamous
cell carcinoma (OPC) have substantially better treatment response and overall survival (OS) …
cell carcinoma (OPC) have substantially better treatment response and overall survival (OS) …
Long-term quality of life after swallowing and salivary-sparing chemo–intensity modulated radiation therapy in survivors of human papillomavirus–related …
Purpose To evaluate long-term health-related quality of life (HRQOL) in 2 prospective
studies of chemo–intensity modulated radiation therapy (chemo-IMRT) for oropharyngeal …
studies of chemo–intensity modulated radiation therapy (chemo-IMRT) for oropharyngeal …
Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01)–A Trans-Tasman Radiation …
D Rischin, M King, L Kenny, S Porceddu… - International Journal of …, 2021 - Elsevier
Purpose The excellent prognosis of patients with low-risk human papillomavirus (HPV)-
associated oropharyngeal squamous cell carcinoma has led to concerns about …
associated oropharyngeal squamous cell carcinoma has led to concerns about …